183 related articles for article (PubMed ID: 15270655)
1. Demethylation of DNA by decitabine in cancer chemotherapy.
Brown R; Plumb JA
Expert Rev Anticancer Ther; 2004 Aug; 4(4):501-10. PubMed ID: 15270655
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation and gene silencing in cancer.
Baylin SB
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S4-11. PubMed ID: 16341240
[TBL] [Abstract][Full Text] [Related]
3. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
4. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition.
Choi SH; Byun HM; Kwan JM; Issa JP; Yang AS
Br J Haematol; 2007 Sep; 138(5):616-23. PubMed ID: 17686055
[TBL] [Abstract][Full Text] [Related]
5. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Stresemann C; Lyko F
Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818
[TBL] [Abstract][Full Text] [Related]
6. Decitabine--bedside to bench.
Oki Y; Aoki E; Issa JP
Crit Rev Oncol Hematol; 2007 Feb; 61(2):140-52. PubMed ID: 17023173
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
Claus R; Almstedt M; Lübbert M
Semin Oncol; 2005 Oct; 32(5):511-20. PubMed ID: 16210092
[TBL] [Abstract][Full Text] [Related]
8. Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells.
Amatori S; Papalini F; Lazzarini R; Donati B; Bagaloni I; Rippo MR; Procopio A; Pelicci PG; Catalano A; Fanelli M
Lung Cancer; 2009 Nov; 66(2):184-90. PubMed ID: 19233506
[TBL] [Abstract][Full Text] [Related]
9. Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S-adenosyl methionine and the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Chik F; Machnes Z; Szyf M
Carcinogenesis; 2014 Jan; 35(1):138-44. PubMed ID: 23985780
[TBL] [Abstract][Full Text] [Related]
10. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine.
Ari F; Napieralski R; Ulukaya E; Dere E; Colling C; Honert K; Krüger A; Kiechle M; Schmitt M
Cell Biochem Funct; 2011 Dec; 29(8):651-9. PubMed ID: 21887697
[TBL] [Abstract][Full Text] [Related]
11. The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells.
Hummel-Eisenbeiss J; Hascher A; Hals PA; Sandvold ML; Müller-Tidow C; Lyko F; Rius M
Mol Pharmacol; 2013 Sep; 84(3):438-50. PubMed ID: 23814180
[TBL] [Abstract][Full Text] [Related]
12. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Liu Z; Marquez M; Nilsson S; Holmberg AR
Oncol Rep; 2008 Jul; 20(1):151-4. PubMed ID: 18575731
[TBL] [Abstract][Full Text] [Related]
13. 5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation.
Füller M; Klein M; Schmidt E; Rohde C; Göllner S; Schulze I; Qianli J; Berdel WE; Edemir B; Müller-Tidow C; Tschanter P
Int J Oncol; 2015 Mar; 46(3):1192-204. PubMed ID: 25501798
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of decitabine as a prototype for an epigenetic drug program.
Rosenfeld CS
Semin Oncol; 2005 Oct; 32(5):465-72. PubMed ID: 16210087
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Pishchik V; Figg WD; Murgo AJ; Steinberg SM
Clin Cancer Res; 2006 Oct; 12(19):5777-85. PubMed ID: 17020984
[TBL] [Abstract][Full Text] [Related]
16. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines.
Schaefer M; Hagemann S; Hanna K; Lyko F
Cancer Res; 2009 Oct; 69(20):8127-32. PubMed ID: 19808971
[TBL] [Abstract][Full Text] [Related]
17. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
Christman JK
Oncogene; 2002 Aug; 21(35):5483-95. PubMed ID: 12154409
[TBL] [Abstract][Full Text] [Related]
18. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Hurtubise A; Momparler RL
Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma.
Patel R; Shervington L; Lea R; Shervington A
Brain Res; 2008 Jan; 1188():173-81. PubMed ID: 18021753
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]